ASX Health Stocks: Combining bisantrene with decitabine effective on solid tumours
Race Oncology jumped 8 per cent after revealing results of studies that showed its lead drug, in combination with another, is a powerful cancer-killer.
Eddy SunartoRace Oncology (ASX:RAC) jumped 8 per cent on Tuesday morning after sharing news that its lead drug, in combination with another, is a powerful cancer-killer.
Recent preclinical studies conducted at Oncolines B.V. in the Netherlands tested
bisantrene (Race’s lead drug) in combination with decitabine to enhance anti-cancer activity.
Results showed that bisantrene and decitabine, used together, have far better cancer cell-killing properties than either drug used alone.
For the latest health news, sign up here for free * daily newsletters
Combining these two drugs at clinical doses significantly boosted cancer cell-killing, with 92 per cent (131 of 143) of the cell lines showing improvement.
These results suggest the combination could be a promising treatment for various cancers, including solid tumors such as those that can form in the lungs, prostate, pancreas, breast, head and neck.
Decitabine is an FDA-approved drug widely used to treat certain blood cancers such asmyelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), but it hasn’t been effective against solid tumours.
However, this study found that decitabine boosts the cancer cell-killing power of bisantrene across a wide range of common human cancers, including many solid tumours.
Race says it will now continue to critically evaluate all opportunities in this space from both a commercial and scientific perspective.
“These results open exciting new treatment opportunities for both bisantrene and decitabine,” said Race’s CEO, Dr Daniel Tillett.
heraldsun. com . au/business/*/asx-health-stocks-combining-bisantrene-with-decitabine-effective-on-solid-tumours/news-story/94bb6a2d5a15636ed3a8c78a0e7a35aa
- Forums
- ASX - By Stock
- RAC media coverage
ASX Health Stocks: Combining bisantrene with decitabine...
-
- There are more pages in this discussion • 216 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.70 |
Change
0.050(3.03%) |
Mkt cap ! $289.6M |
Open | High | Low | Value | Volume |
$1.66 | $1.70 | $1.63 | $181.9K | 109.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 11946 | $1.70 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.75 | 27579 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 6605 | 1.635 |
1 | 10752 | 1.615 |
2 | 20016 | 1.610 |
2 | 21000 | 1.600 |
1 | 1279 | 1.555 |
Price($) | Vol. | No. |
---|---|---|
1.750 | 14579 | 3 |
1.755 | 990 | 1 |
1.760 | 500 | 1 |
1.800 | 824 | 2 |
1.820 | 4000 | 3 |
Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online